TNXP

Tonix Pharmaceuticals Holding Corp.

Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001430306 Biotech & Drug Discovery

$5.30 +0.13 (+2.51%)

Oct 26 4:00 PM ET · prev $5.17

Market cap

$88.0M

Micro cap

Consensus

Buy

90% Buy or better · 10 analysts

Median target

🔒 Subscribers only

Next earnings

Nov 9

in 13 days

1 year

−74.0%

from $20.35 · Oct 27

30 days

−46.5%

from $9.90

52-week range

$5.13–20.35

−74% from high · low Oct 22

Avg volume 20D

1.03M

shares / day

Short interest

🔒 Subscribers only

Insider net

+$458.8K

4 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Reddit crowd

58°

Warm · 2 mentions this week

SecBot read BULLISH 8 reports · 90 days

Balance 1 bearish · 4 bullish · 1 mixed · 2 neutral oldest → newest, height = score

Avg score

·High conf. 7/8 ·Next Earnings date, Nov 9, 2026

Strongest BULLISH Tonix Pharmaceuticals disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M, up 27-36% sequentially…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 5 Tonix Pharmaceuticals announced the publication of pharmacokinetic d…
B Mar 18 1 insider buy $223.3K at $14.89
B Mar 31 1 insider buy $63.1K at $12.62
B Jun 8 to Jun 12 3 days of insider buys: $132.1K by 3 insiders, avg $11.57
A Jun 25 Raymond James initiates
B Aug 20 to Aug 27 2 days of insider buys: $40.2K by 2 insiders, avg $13.39
R Oct 2 Tonix received a Paragraph IV ANDA notice from Dr. Reddy's Laborator…
E Oct 19 FDA: Tonix Pharmaceuticals to Present an Analysis of Phase 3 Da…

Signal stack

Where each data set points today.

InsidersBULLISH

4 insiders bought $458.8K at an average $13.33. No open-market sales. Price is 60% below their cost.
InstitutionsBULLISH

Q2 2026: 23 added (0 new), 4 trimmed or exited.
AnalystsBULLISH

9 of 10 rate it Buy or better.
TrendDOWNTREND

48% below its 50-day average. New closing low $5.13 on Oct 22.
SocialQUIET

Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	ADD	1,398,041	$17.8M
Point72 Asset Management, L.P.	DOUBLED	1,166,752	$14.9M
MILLENNIUM MANAGEMENT LLC	DOUBLED	966,932	$12.3M
VANGUARD CAPITAL MANAGEMENT LLC	ADD	691,895	$8.8M
GEODE CAPITAL MANAGEMENT, LLC	ADD	395,260	$5.0M
CITADEL ADVISORS LLC	TRIM	195,859	$2.5M
BALYASNY ASSET MANAGEMENT L.P.	TRIM	132,591	$1.7M
GOLDMAN SACHS GROUP INC	ADD	98,356	$1.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts

Buy 90% rate it Buy or better

Strong Buy3Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Oct 26, 2026	🔒 Fresh data, subscribers only INITIATE	INITIATE
Jun 25, 2026	Raymond James INITIATE	INITIATE	Strong Buy
May 4, 2026	TD Cowen INITIATE	INITIATE	Buy

Crowd this week 58° Warm 1 bullish · 0 bearish

Mentions, 7 days 2 2 in posts · 0 in comments

Insider ledger

Form 4

$458.8K

bought · 4 insiders

sold · 0 insiders

−60.2%

vs their $13.33 cost

Date	Insider	Type	Value
Aug 27, 2026	LEDERMAN SETH Chief Executive Officer	BUY	$27.6K
Aug 20, 2026	BAGGER RICHARD H Director	BUY	$12.6K
Jun 30, 2026	SAENGER BRADLEY Chief Financial Officer	OTHER	$15.9K
Jun 12, 2026	Taylor Carolyn E. Director	BUY	$14.9K
Jun 9, 2026	LEDERMAN SETH Chief Executive Officer	BUY	$58.9K
Jun 8, 2026	Stillwell Richard Newcomb Director	BUY	$58.3K
May 12, 2026	BAGGER RICHARD H Director	AWARD	22,700 sh
May 12, 2026	Taylor Carolyn E. Director	AWARD	22,700 sh

Earnings setup

Estimates

Nov 9

reports in 13 days

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only